Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C

US5344841A · kind A · utility

Assignee

• Sphinx Pharmaceuticals Corporation · US

Inventors

• Jack B. Jiang · Chapel Hill, US
• Mary G. Johnson · Carrboro, US

Key dates

• Filing date: Jun 8, 1992
• Grant date: Sep 6, 1994
• Expiry date: Jun 8, 2012

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/24
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

##STR1## The present invention provides novel substituted anthraquinones having formula (.alpha.), wherein R.sub.1 and R.sub.2 are independently H, C.sub.1 -C.sub.10 alkyl, aryl, arylalkyl, alkylaryl, or R.sub.1 and R.sub.2 taken together with the adjacent nitrogen atom N form a substituted or unsubstituted cyclic ring which may contain additional heteroatoms; n and m are independently 1, 2, or 3; A is halogen, OH, alkoxy, OCO(NR.sub.3 R.sub.4), S--C(NH.sub.2)=NR.sub.5, or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R.sub.3, R.sub.4, and R.sub.5 are independently H, alkyl, or aryl; X is H, OH, NR.sub.6 R.sub.7, Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR.sub.8, or CONR.sub.9 R.sub.10 ; and R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are independently H, lower alkyl, or aryl useful for inhibiting protein kinase C and treating conditions related to, or affected by inhibition of protein kinase C, particularly cancer tumors, inflammatory disease, reperfusion injury, and cardiac dysfunctions related to reperfusion injury.